Principles and practical strategies to carry out immunotherapy in malignant genitourinary neoplasms
Principles and practical strategies to carry out immunotherapy in malignant genitourinary neoplasms is organized by ReachMD.
Release Date: 07/01/2021
Expiration Date: 06/01/2022
This activity is aimed at oncologists, urologists, surgeons, pharmacists, medical associates (PA), oncology nurses and other health professionals who perform treatments against different types of genitourinary cancer.
Statement of accreditation:
This activity was planned and thought for by a team of healthcare professionals, and participants will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change
Clinician Credit Allocation:
AXIS Medical Education allocates a maximum of 1.0 AMA PRA Category 1 Credit (s) ™ to this material. Doctors can only request the corresponding credits based on their participation in the activity
Medical Associate (PA) Credit Allocation
AXIS Medical Education is authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit to planned activities in accordance with the CME Criteria of the AAPA. 1.0 AAPA Category 1 CME credits correspond to this activity. Approval is valid until 06/01/2022. Medical associates can only request the corresponding credits based on their participation.
Advances in immune checkpoint inhibitor therapy are transforming the way healthcare professionals treat and approach urothelial carcinoma (UC) and renal cell carcinoma (RCC). Due to the approval of immune checkpoint inhibitors for the treatment of metastatic UC and RCC in recent years, and from new evidence, it can be difficult to understand how to best incorporate these therapies into current treatment strategies.
This activity will examine the latest clinical advances, the most current information, and guideline recommendations for treating advanced cases of urothelial carcinoma and renal cell carcinoma with immunotherapy.
At the end of this educational activity, participants will be better able to do the following:
• To assess the evidence supporting the use of immune checkpoint inhibitors for the first-line treatment of urothelial carcinoma and advanced stage or metastatic renal cell carcinoma.
• To analyze the role of first-line maintenance treatment with immune checkpoint inhibitors for metastatic urothelial carcinoma.
• To compare survival data with sequential immunotherapy and traditional chemotherapy as first-line treatment for metastatic urothelial carcinoma
• Develop strategies for evidence-based sequence treatments with immune checkpoint inhibitors for the first-line treatment of urothelial carcinoma and advanced-stage or metastatic renal cell carcinoma
- IPCE : 1
- CME : 1
- Credits : 1
- Hours : 1
Toll free Number
Browse CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine